iPierian Inc. to Present at Future Leaders in the Biotech Industry Conference

SOUTH SAN FRANCISCO, CA--(Marketwire - April 12, 2011) - iPierian Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, announced today that Michael C. Venuti, Ph.D., chief executive officer, will present at the Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center, New York, New York. Their presentation will take place on Friday, April 15, 2011, at 11:30 a.m., Eastern Daylight Time. Dr. Venuti will present an overview of iPierian and discuss the company's discovery platform, therapeutic pipeline, business strategy and upcoming milestones.

About iPierian
iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and the discovery and development of innovative therapeutics using patient-derived cells as models of human disease. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, as well as type 2 diabetes.

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute of Cardiovascular Disease, The University of California, San Francisco (UCSF), and Kyoto University. Our SAB members include George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, Deepak Srivastava, M.D., of The Gladstone Institute of Cardiovascular Disease and UCSF, and Shinya Yamanaka, M.D, PhD., of Kyoto University, the Center for iPS Cell Research and Application (CiRA), and The Gladstone Institute of Cardiovascular Disease.

iPierian is located in South San Francisco, California. For more information, please visit www.ipierian.com.

Danielle Bertrand
Email Contact

Matthew Plunkett

Back to news